Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 318

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 318
---
 compiled by the Alzheimer’s Association (alz.org):

| ● | The population of Americans age 65 and older is projected 
 to grow from 58 million in 2021 to 88 million by 2050.    |

| ● | The percentage of people with Alzheimer’s dementia increases                                                 
 with age: from 5.1% of people age 65 to 74 up to 33.4% of people age 85 and older have Alzheimer’s dementia. |

| ● | Almost 2/3 of American with AD are women. Of the 6.7 million                                                      
 people age 65 and older with Alzheimer’s dementia in the United States, 4.1 million are women and 2.6 million are 
 men. This represents 12% of women and 9% of men age 65 and older in the United States.                            |

| ● | By 2025, the number of people age 65 and older with Alzheimer’s                                             
 dementia is projected to reach 7.2 million — an 11% increase from the 6.7 million age 65 and older affected 
 in 2023.                                                                                                    |

<div align='center'>182</div>

| ● | The figures in the table above only reflect information pertaining 
 to the United States.                                              |

| ● | By 2060, the number of people age 65 and older with Alzheimer’s                                                                    
 dementia is projected to reach 13.8 million, barring the development of medical breakthroughs to prevent, slow or cure Alzheimer’s 
 disease.                                                                                                                           |

| ● | 240+ clinical trials on MCI/AD are currently ongoing in the                 
 US; average number of patients: 220 per trial (source: clinicaltrials.gov); |

| ● | The total number of patients screened per trial is at least               
 the number of patients enrolled and frequently two to five times greater. |

Broad screening of population in high-risk groups(e.g. for AD registries) presents a separate business opportunity for CogniMIR.

By 2025, an estimated 7.2 million
Americans will develop Alzheimer’s dementia. This number is expected to reach 13.8 million by 2060. Data suggest that annually
about 500,000 cases are detected in the US. Based on the population statistics the number of new AD cases in Europe can be estimated
at 830,000 per year and in Japan at 216,000 cases per year.

The potential worldwide market